Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: A retrospective claims database analysis

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 836-848

  Kim, Edward ^a   Maclean, Ross ^a   Ammerman, Diane ^a   Jing, Yonghua ^a   Pikalov, Andrei ^b   You, Min ^a   Van Tran, Quynh ^b   L'Italien, Gilbert ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

adjunctive treatment; aripiprazole; bipolar disorder

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MONITORING; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 65549091830     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.022     Document Type: Article

References (29)

1. Simon G.E., and Unützer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 50 (1999) 1303-1308
2. Stender M., Bryant-Comstock L., and Phillips S. Medical resource use among patients treated for bipolar disorder: A retrospective, cross-sectional, descriptive analysis. Clin Ther 24 (2002) 1668-1676
3. Lish J.D., Dime-Meenan S., Whybrow P.C., et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 31 (1994) 281-294
4. Li J., McCombs J.S., and Stimmel G.L. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord 71 (2002) 131-139
5. Blanco C., Laje G., Olfson M., et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 159 (2002) 1005-1010
6. Guo J.J., Keck Jr. P.E., Corey-Lisle P.K., et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 67 (2006) 1055-1061
7. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 Suppl (2002) 1-50
8. Suppes T., Dennehy E.B., Hirschfeld R.M., et al., the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66 (2005) 870-886
9. Goodwin G.M., and the Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psycho-pharmacology. J Psychopharmacol 17 (2003) 149-173 discussion 147
10. Grunze H., Kasper S., Goodwin G., et al., the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 4 (2003) 5-13
11. Yatham L.N. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am 28 (2005) 325-347
12. Bowden C.L. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 65 Suppl 15 (2004) 21-24
13. Guo J.J., Keck Jr. P.E., Li H., et al. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health 11 (2008) 416-423
14. Shapiro D.A., Renock S., Arrington E., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
15. Burris K.D., Molski T.F., Xu C., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
16. Tadori Y., Miwa T., Tottori K., et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique anti-psychotic. Eur J Pharmacol 515 (2005) 10-19
17. Tadori Y., Forbes R.A., McQuade R.D., and Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 597 (2008) 27-33
18. Jordan S., Koprivica V., Dunn R., et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483 (2004) 45-53
19. Jordan S., Koprivica V., Chen R., et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 (2002) 137-140
20. Abilify (aripiprazole) [prescribing information]. (2008), Bristol-Myers Squibb/Otsuka America Pharmaceutical Inc;, Princeton, NJ. http://www.abilify.com/pdf/pi.aspx Accessed April 4, 2009
21. Vieta E., T'joen C., McQuade R.D., et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonrespon-sive to valproate/lithium monothera-py: A placebo-controlled study. Am J Psychiatry 165 (2008) 1316-1325
22. Vieta E., Bourin M., Sanchez R., et al., the Aripiprazole Study Group. Effectiveness of aripiprazole v. halo-peridol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187 (2005) 235-242
23. Keck Jr. P.E., Marcus R., Tourkodimitris S., et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160 (2003) 1651-1658
24. Sachs G., Sanchez R., Marcus R., et al., the Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 20 (2006) 536-546
25. Keck Jr. P.E., Calabrese J.R., McQuade R.D., et al., the Aripiprazole Study Group. A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67 (2006) 626-637
26. Keck Jr. P.E., Calabrese J.R., McIntyre R.S., et al., the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 68 (2007) 1480-1491
27. International Classification of Diseases, Ninth Revision, Clinical Modification. http://icd9cm.chrisendres.com/icd9cm/index.php Accessed April 17, 2009
28. Najt P., Perez J., Sanches M., et al. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol 17 (2007) 313-320
29. Citrome L., Reist C., Palmer L., et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 108 (2009) 238-244